CONTEMPORARY studies ofhost responses to malignant cells have concentrated on the mechanics of adaptive or acquired immunity, and have in consequence emphasized the role of highly specific cellmediated or humoral reactions directed against tumour-specific transplantation antigens (TSTA). This is however only one rather limited aspect of immunity, which overlooks phylogenetically much older mechanisms responsible for innate resistance. Hibbs, Lambert and Remington (1972) have shown that macrophages, when suitably activated, exert a cytotoxic effect which discriminates between transformed and untransformed target cells in vitro, yet shows no evidence of immunological specificity. Furthermore, Currie and Basham (1975) have demonstrated that malignant target cells can be lysed by a factor released from activated macrophages, whereas the corresponding normal cells are resistant to lysis. Since Evans (1972) had shown that many animal tumours are infiltrated by host macrophages and that the extent of infiltration reflects the biological behaviour of the tumours, we have been examining the hypothesis that cells of macrophage-1 monocyte lineage may be significant limiting factors in host resistance to tumour growth. Such a role for these cells would not necessarily be restricted by immunological specificity in the conventional sense, but may be based on a more general capacity for distinguishing between self and non-self (or normal and abnormal) such as that seen in invertebrates and in lower vertebrates.
We have therefore undertaken a series of studies of monocyte and macrophage numbers and function in patients with malignant disease. This first paper describes experiments designed to count monocytes in the peripheral blood of normal individuals and of patients with malignant melanoma.
Unfortunately the enumeration of monocytes in the peripheral blood, using conventional morphological criteria, is unlikely to be reliable, since subjective observer error cannot be excluded. A classical monocyte is readily recognizable and distinguishable from a classical lymphocyte, but in a stained smear of peripheral blood, especially in disease, there are so many equivocal and intermediate forms that we felt obliged to abandon morphology as a diagnostic criterion, a conclusion similar to that drawn by Hirsch and Fedorko (1970) . In consequence we decided, for the purposes of this study, to define the monocyte in operational terms as that mononuclear cell in the peripheral blood which is capable, under standard conditions, of differentiating into a macrophage, i.e. is a macrophage precursor (MP). For this purpose we have adapted an assay described by Krikorian et al. (1975) and have developed a clinically applicable micromethod.
MATERIALS AND METHODS
Patients.-In this study, 34 patients presenting to this hospital with a histologically proven diagnosis of malignant melanoma were studied. These were patients with recurrent, disseminated or inoperable disease. Blood samples were taken before any treatment was given by us, although several of the patients had undergone previous surgery at other centres, usually several weeks or even months before being studied. Fourteen of the patients had been rendered clinically diseasefree by this earlier surgery but were all of poor prognosis, with a high risk of tumour recurrence. Indeed by the time this paper was written, up to 8 months later, 6 of these 14 had already developed further disease.
Macrophage precursor assay.-Defibrinated peripheral venous blood was layered on to an equal volume of a Ficoll-Triosil mixture (Lymphoprep, Nygaard) and centrifuged as described by Boyum (1968) (Sanford et al., 1951) was added to each well and the plate was allowed to stand for 30 min at room temperature. After vigorous agitation by repeated aspiration with a 50-pl micro pipette, the detached nuclei were counted in a haemocytometer. Microscopic examination of the plates indicated that this procedure removed all the cell nuclei from the plastic surface. Each reading represents the mean of at least 5 replicate wells. The results were expressed as a yield of macrophage precursors (MPC) per ml blood. This was derived as follows:
Mean number of macrophages/well x Mononuclear cell yield 2 x 105 from 1 ml blood Preliminary studies had revealed that FicollTriosil separation methods gave a yield of over 90% of the mononuclear cells in the blood. Although occasional polymorphonuclear leucocyte contamination was encountered, more often from the patients than from the normals, their presence did not seem to inhibit the development of macrophages in vitro. However, by employing narrow centrifuge tubes and spinning for at least 45 min, we managed to avoid significant polymorphonuclear cell contamination in the studies described.
RESULTS
We examined the influence of many potential variables on the performance of this assay before applying it to a series of patients. Firstly it was found that defibrinated blood always gave higher and more reproducible results than when using heparin as an anticoagulant. The presence of contaminant platelets in cultures obtained from heparinized blood was always associated with poor or absent macrophage development, an observation previously reported by Krikorian et al. (1975 
Serum factors
Since many of the patients showed very depressed MP values (see below), we examined the possibility that the presence of inhibitory, or even the absence of stimulatory, serum factors may be responsible. This was done by incubating mononuclear cells from normal individuals in serum from melanoma patients and vice versa. These studies provided no evidence for suppressive or stimulatory serum factors. Occasionally, sera did cause a degree of inhibition, but since these were found in allogeneic combinations, the possibility of anti-HLA or even blood group antibodies cannot be excluded in all cases. On two occasions, we tested the effect of allogeneic patients' sera on mononuclear cells from normal Group 0-ve donors. As can be seen from the Table, The assay was performed on blood obtained from 20 normal healthy donors (aged 17-60 years) and on 34 patients with malignant melanoma of similar age range and sex distribution. The results are shown in the Figure. In normal donors there was a wide range of results, with a mean value of 7-6 ± 4-3 (s.d.) x 104 MP/ ml, whereas the melanoma patients showed much lower levels when compared to these, i.e. 1.1 ± 1.1 x 104 MP/ml. This dramatic difference seems to indicate that "final common pathway" malignant melanoma is associated with a severe deficiency in the capacity of peripheral blood monocytes to differentiate into macrophages, although preliminary studies in other tumours indicate that such a finding is not unique to melanoma. Further studies of patients with non-malignant disease are in progress.
Monocyte counts and MPs
By conventional morphological methods using stained smears, the number of monocytes in the peripheral blood of normal adults ranged from 200 to 800/mm3. In these normal individuals the MP count was very much lower (i.e. about 33-100/mm3) and there was no correlation with the morphological monocyte count. In the malignant melanoma patients this discrepancy was even greater. Furthermore, of the 34 untreated patients the absolute morphological monocyte count was within the normal range in 24 cases (200-800/ mm3) although the MP count was severely "subnormal" in most of them.
MPs and clinical stage of the disease Although the majority of patients with malignant melanoma seen at this centre have disseminated, recurrent or inoperable disease, many are seen who have been rendered clinically disease-free by prior surgery but who are likely to recur rapidly-e.g. patients with metastatic disease who have been treated by radical surgical excision. Of the 34 cases studied, 14 fell into this category, i.e. clinically disease-free but with a high risk of recurrence, whereas the remaining 20 cases all had clinically detectable active disease. There is, however, no difference in MP values between these 2 groups. In other words, the detectable defect in peripheral blood MP activity is not associated with overt tumour burden. Prospective studies to determine the prognostic significance, if any, of MP levels are in progress in both the "disease-free at risk" and the overt disease groups. Furthermore, all the patients studied were in the "final common pathway" of their disease. We are therefore unable as yet to say whether the MP defect is restricted to patients with a poor prognosis.
DISCUSSION
When mononuclear cell suspensions from normal individuals are cultured under standard conditions, large numbers of macrophages develop over a period of 7 days. Similar suspensions obtained from patients with malignant melanoma provide only scanty macrophages. This apparent defect in "macrophage precursors" (MP) can be explained in several ways. Using conventional morphological criteria, we found that the patients had peripheral blood monocyte counts broadly within the normal range. This observation, confirmed by enzyme histochemical methods (to be published), suggests that an overall quantitative monocyte defect cannot be incriminated. However, it is conceivable that a quantitative defect in a specialized subset of monocytes could be responsible, a subset committed to maturation, whose absence would go undetected by conventional counting methods. Alternatively, a qualitative explanation involving a generalized defect in monocyte differentiation could also account for our observations. Snyderman, Blaylock and Pick (1975) have reported that tumours release a factor which can inhibit accumulation of macrophages at inflammatory sites in vivo and abrogate monocyte chemotaxis in vitro. However, we have been unable to demonstrate any consistent effects of patients' sera, and are therefore led to conclude that the low MP levels detected in the patients probably represent an intrinsic cellular defect in the peripheral blood monocytes rather than variations in hypothetical serum factors. Dizon and Southam (1963) , in a study of skin-window cellular infiltrates, suggested that patients with "advanced" cancer had a reduced capacity to mobilize tissue macrophages. Such a finding could be explained by the sequestration of monocytes within the growing tumours, as suggested in an animal model by Eccles and Alexander (1974) . However, studies of the macrophage content of melanoma biopsy samples indicate (Currie, 1976 ) that significant macrophage infiltration is associated only with localized disease. Since the patients examined in the present study were those with massive tumour burdens or with no detectable tumour at all, such a sequestration hypothesis cannot explain the apparent deficit of MPs in their peripheral blood. Furthermore, in their experimental animal model Eccles and Alexander (1974) have shown that rats bearing tumours substantially infiltrated by host macrophages show defective delayed cutaneous hypersensitivity reactions, and they went on to show that this apparent energy was due to a defect in macrophage infiltration, i.e. a defect of inflammation. The nature of this defect, qualitative or quantitative, was unclear. However, Eccles, Bandlow and Alexander (1976) argue that the defect is qualitative, since they have subsequently shown that such apparently anergic rats show a significant monocytosis rather than a monocytopenia. Furthermore, Normann and Sorkin (1976) have confirmed this observation in rats bearing DMBA-induced tumours.
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